|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To determine the possibility of the disturbance in neuropeptides in human obesity and their consequent changes in response to negative energy balance, we evaluated plasma and cerebrospinal fluid (CSF) leptin, NPY, and alpha-MSH levels in obese women before and after weight loss in comparison with normal control women.
|
11600552 |
2001 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The regulation of NPY/NPY-R expression and function appears to be part of a complex system controlling multiple physiological functions, and its disruption might be relevant in the pathophysiology of disease states such as obesity.
|
12570784 |
2003 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
NPY‑ergic neurons in the central amygdala were activated by chronic cold exposure in mice on HFD via neuronal pathways to decrease BDNF and increase GHRH mRNA expression, possibly contributing to the development of obesity and impairment of glucose homeostasis.
|
30106124 |
2018 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that NPY mRNA expression was higher in obese than in normal weight humans (p<0.05) in both subcutaneous and visceral adipose tissues and was significantly greater in visceral when compared with subcutaneous fat in overall (p<0.01), obese (p<0.05) and normal weight humans (p<0.05).
|
23838112 |
2013 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
While in heterozygous mice the adipogenic effect of NPY is important, in homozygous mice inhibition of sympathetic tone leading to decreased lipolytic activity and impaired brown fat function, as well as increased endocannabinoid levels contribute to obesity.
|
26681068 |
2016 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Ghrelin and NPY mRNA levels followed the same trend and were significantly higher in the hypothalamus in obese compared to lean subjects, suggesting a central origin for the increased protein content in the obese subjects.
|
16957407 |
2006 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Several studies have shown that obesity is associated with increased levels of NPY in the hypothalamus.
|
28954935 |
2018 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the mechanism of the effect of topiramate to create a state of obesity is thought to involve the decrease in the levels of NPY and FTO.
|
28914170 |
2019 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Abnormal regulation of NPY is involved in the development of a wide range of diseases, including obesity, hypertension, atherosclerosis, epilepsy, metabolic disorders, and many cancers.
|
29310113 |
2018 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Modest overexpression of neuropeptide Y in the brain leads to obesity after high-sucrose feeding.
|
11334428 |
2001 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The role of NPY in metabolic homeostasis: implications for obesity therapy.
|
11060746 |
2000 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Together, these results indicate that DMH NPY plays an important role in modulating food intake and energy balance and its dysregulation causes disordered energy balance leading to obesity.
|
19129396 |
2009 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
These data illustrate that mild cold stress is a critical factor preventing the development of obesity in Snord116<sup>-/-</sup> mice via the NPY system.
|
27823858 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Centrally administered NPY causes robust increases in food intake and body weight and, with chronic administration, can eventually produce obesity.
|
17785427 |
2007 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results provide evidence that the functionally relevant SNP in the NP-Y promoter gene affects body fat distribution and serum leptin levels in women, pointing towards possible behavioral effects of NPY in obesity.
|
23652383 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The neuropeptide Y (NPY) Y<sub>4</sub> receptor (Y<sub>4</sub>R) is involved in energy homeostasis and considered a potential drug target for the treatment of obesity.
|
28345900 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The neuropeptide Y system has proven to be one of the most important regulators of feeding behaviour and energy homeostasis, thus presenting great potential as a therapeutic target for the treatment of disorders such as obesity and at the other extreme, anorexia.
|
21545413 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Loss of neuropeptide Y (NPY) can correct the obesity syndrome of mutant mice lacking of leptin (ob/ob).
|
28864114 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
These various effects plus a number of others make NPY an attractive target for the potential treatment of human diseases, such as obesity, metabolic disorders, hypertension and heart failure.
|
12678499 |
2003 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
As NPY and NPY2R are interesting candidate genes for obesity, we hypothesized that a genetic variation in these genes might be implicated in the pathogenesis of obesity.
|
28857123 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, long-term interference with the NPY system to target obesity or cancer related aspects needs to consider potential side effects on bone health.
|
21439311 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The objective of the present study was to evaluate the association of single nucleotide polymorphisms (SNPs) in the NPY gene with obesity, metabolic syndrome features, and inflammatory and cardiovascular disease (CVD) risk biomarkers in Spanish children.
|
23624317 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Reduced dopaminergic neurotransmission in the suprachiasmatic nucleus of seasonally obese animals appears to drive noradrenalin and NPY mediated transmissions in other nuclei to induce the obesity syndrome at the appropriate time of year.
|
14623356 |
2003 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Ultimately, characterization of the specific "feeding' receptors which mediate NPY's central effects on energy homeostasis may provide opportunities for designing drugs to manipulate and appetite and energy balance in man, notably obesity and the cachexia commonly associated with malignancy and chronic infection.
|
8871182 |
1996 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Similarly, mice overexpressing NPY in noradrenergic neurons (OE-NPY<sup>DBH</sup>) display obesity and impaired glucose metabolism.
|
28468933 |
2017 |